Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides results from the ECOG trial in smoldering multiple myeloma (MM).
Learn about the benefits of risk-reducing surgeries in young BRCA mutation carriers with a history of breast cancer.
Get insights into the PATINA Phase 3 trial studying Palbociclib in ER+/HER2+ Metastatic Breast Cancer, and how it aims to improve outcomes in these patients.
Explore how CDK4/6 inhibitors are revolutionizing early breast cancer treatment. Find out about the expanded treatment scope and long-term efficacy.
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
New data from DESTINY-Breast06 study presented at SABCS 2024. Explore efficacy of ENHERTU in hormone receptor-positive metastatic breast cancer patients.
Get critical insights into advanced breast cancer treatment from the Phase 3 EMBER-3 trial. Explore the efficacy of Imlunestrant and its potential in improving patient…
FDA approves combination treatment for advanced non-small cell lung cancer (NSCLC) targeting specific EGFR mutations. Learn about the MARIPOSA trial results,…
FDA approved pembrolizumab (Keytruda) combined with chemotherapy for mesothelioma treatment. A new option for patients battling this aggressive disease.
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.
Download Slides: https://oncologytube.com/slides-fda-approves-kisqali-ribociclib-for-early-high-risk-breast-cancer/The FDA has approved Kisqali (ribociclib) …
